Division of Biogen Inc.
Latest From Stromedix Inc.
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michael Gilman, PhD, CEO
Brad Maroni, MD, CMO
Shelia Violette, PhD, VP, Rsch.
- Contact Info
Phone: (617) 674-8400
One Canal Park, Ste. 1120
Cambridge, MA 02141
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.